Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Oct 14, 2021
Summit, NJ, USA 14 Oct 2021 Seqirus, a global leader in influenza prevention, and a business of CSL Limited (ASX:CSL), today announced that The New England Journal of Medicine has published...
-
Oct 14, 2021
• Expert modelling points to a more severe influenza season than in previous years.1 • The lifting of restrictions to reduce COVID-19 transmission may leave vulnerable people – with reduced...
-
Oct 4, 2021
• Seqirus will develop and evaluate two influenza A(H2Nx) virus vaccine candidates in support of U.S. government pandemic preparedness objectives • Company will utilize its combination of...
-
Aug 19, 2021
• Appoints Roberta Duncan as new program lead to drive technology advancement • Accelerates development of sa-mRNA vaccine candidates for seasonal and pandemic influenza Summit, NJ, USA 19 Aug...
-
Jul 27, 2021
The company is prepared to meet the record levels of demand seen during the 2020/21 influenza season amidst the ongoing COVID-19 pandemic. Summit, NJ, USA 27 Jul 2021 Seqirus offers a...